Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Krajnović, Milena ^a   Radojković, Milica ^b,c   Davidović, Radoslav ^a   Dimitrijević, Bogomir ^a   Krtolica, Koviljka ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Clinical Center Dr Dragisa Misovic   (Serbia)

Author keywords

DAPK; Follicular lymphoma; Methylation; MGMT; p15; p16

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P15; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; EPIGENETICS; FAILURE FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; GENETIC ASSOCIATION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DEATH-ASSOCIATED PROTEIN KINASES; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EPIGENESIS, GENETIC; FEMALE; GENES, P16; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM GRADING; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84871603787     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0441-3     Document Type: Article

References (48)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphoma: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780-95.
2. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. ew treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447-52.
3. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saes R, Au WJ, Bellei M, Brice P, Cabbalero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-65.
4. Sehn LH, Fenske TS, Laport GG. Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:S82-91.
5. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440-3.
6. Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia. 2007;21:18-29.
7. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the top of the iceberg. Clin Immunol. 2003;109:80-8.
8. Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, Carbone A, Gaidano G. Abberant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica. 2004;89:154-64.
9. Toyota M, Issa JP. The role of DNA hypermethylation in human neoplasia. Electrophoresis. 2000;21:329-33.
10. Martinez-Delgado B, Robledo M, Arranz E, Osorio A, Garcia MJ, Echezarreta G, Rivas C, Benitez J. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphoma. Leukemia. 1998;12:937-41.
11. Villuendas R, Sanchez-Beato M, Koh JC, Saez AI, Martinez-Delgado B, Garcia JF, Mateo MS, Sanchez-Verde L, Benitez J, Martinez P, Piris MA. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol. 1998;153:887-97.
12. Baur AS, Shaw P, Burri N, Delacrétaz F, Bosman FT, Chaubert P. Frequent methylation silencing of p15 INK4b (MTS2) and p16 INK4a (MTS1) in B-cell and T-cell lymphomas. Blood. 1999;94:1773-81.
13. Chim CS, Wong KY, Loong F, Lam WW, Srivastava G. Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma. Hum Pathol. 2007;38:1849-57.
14. Voso MT, Gumiero D, D'Alo' F, Guidi F, Mansueto G, Di Febo AL, Massini G, Martini M, Larocca LM, Hohaus S, Leone G. DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. Haematologica. 2006;91:1252-6.
15. Guo J, Burger M, Nimmrich I, Maier S, Becker E, Genc B, Duff D, Rahmatpanah F, Chitma-Matsiga R, Shi H, Berlin K, Huang THM, Caldwell CW. Differential DNA methylation of gene promoters in small B-cell lymphomas. Am J Clin Pathol. 2005;124:430-9.
16. Bennett LB, Schnabel JL, Kelchen JM, Taylor KH, Guo J, Arthur GL, Papageorgio CN, Shi H, Caldwell CW. DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma. Genes Chromosomes Cancer. 2009;48:828-41.
17. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-12.
18. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res. 2000;462:83-100.
19. Cohen O, Kimchi A. DAP-kinase: from functional gene cloning to establishment of its role in apoptosis and cancer. Cell Death Differ. 2001;8:6-15.
20. Ng MH. Death associated protein kinase: from regulation of apoptosis to tumor suppressive function and B cell malignancies. Apoptosis. 2002;7:261-70.
21. Radojkovic M, Ristic S, Colovic M, Cemerikic-Martinovic V, Radojkovic D, Krtolica K. Molecular characteristics and prognostic significance of Bcl2/IgH gene rearrangement in Serbian follicular lymphoma patients. Neoplasma. 2008;55:421-7.
22. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos G. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-53.
23. Krtolica K, Krajnović M, Ušaj-Knežević S, Babić D, Jovanović D, Dimitrijević B. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol. 2007;13:1187-94.
24. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. 2nd ed. New York: Cold Spring Harbor Laboratory Pres; 1989.
25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-6.
26. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-7.
27. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999;93:4347-53.
28. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525-30.
29. Garcia MJ, Martinez-Delgado B, Cebrian A, Martinez A, Benitez J, Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's lymphoma and CD30-positive non-Hodgkin lymphomas. Am J Pathol. 2002;161:1007-13.
30. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Kong WK, Mao L. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res. 2004;10:6119-25.
31. Shiozawa E, Takimoto M, Makino R, Adachi D, Saito B, Yamochi-Oniyuka T, Yamochi T, Shimozuma J, Maeda T, Kohno Y, Kawakami K, Nakamaki K, Tomoyasu S, Shiokawa A, Ota H. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leuk Res. 2006;30:859-67.
32. Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol. 2008;19:1774-86.
33. Lee M, Han WS, Kim OK, Sung SH, Cho MS, Lee SN, Koo H. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol Res Pract. 2006;202:415-24.
34. Sancez-Beato M, Saez AI, Navas IC. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol. 2001;159:205-13.
35. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INKA characterize the major types oh hematological malignancies. Cancer Res. 1997;57:837-41.
36. Kraguljac N, Krajnović M, Dimitrijević B, Mihaljević B, Gotić M, Krtolica K. Frequency of aberrant promoter methylation of p15INK4B and O6-methylguanine-DNA methyltransferase genes in B-cell non-Hodgkin lymphoma: a pilot study. Arch Biol Sci. 2010;62:211-21.
37. Kraguljac KN, Krajnović M, Bogdanović A, Suvajdžić N, Jovanović J, Dimitrijević B, Čolović M, Krtolica K. Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells. Med Oncol. 2012;29:3547-56.
38. Wemmert S, Bettscheider M, Alt S, Ketter R, Kammers K, Feiden W, Steudel WI, Rahnenführer J, Urbschat S. p15 promoter methylation - a novel prognostic marker in glioblastoma patients. Int J Oncol. 2009;34:1743-8.
39. Deneberg S, Grovdal M, Karimi M, Jansson M, Nahi H, Corbaciogly A, Gaidzik V, Dohner K, Paul C, Ekstrom TJ, Hellstrom-Lindberg E, Lehmann S. Gene - specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia. 2010;24:932-41.
40. Kim M, Oh B, Kim SY, Park HK, Hwang SM, Kim TY, She CJ, Yang I, Yoon SS, Yoon JH, Lee DS. p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndrome in a dose dependent manner: quantitation using pyrosequencing study. Leuk Res. 2010;34:718-22.
41. Elenitoba-Johnson KSJ, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood. 1998;91:4677-85.
42. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene. 2004;23:1-8.
43. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG. Hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002;94:26-32.
44. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-4.
45. Tozawa T, Tamura G, Honda T, Nawata S, Kimura W, Makino N, Kawata S, Sugai T, Suto T, Motoyama T. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci. 2004;95:736-40.
46. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jafe ES, Raffeld M. p53 mutations is associated with progression in follicular lymphomas. Blood. 1993;82:1994-2004.
47. O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, MacDougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister A, Fitzgibbon J. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood. 2008;112:3126-9.
48. Jaffe E, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietics and Lymphoid Tissues. Lyon: IARC Press; 2001.